Frederick Lief Ruberg MD – Chief, Cardiovascular Medicine

Professor, Cardiovascular Medicine

Professor, Radiology

75 E. Newton St | (617) 638-8968
f.ruberg@bmc.org
frederick.ruberg@bmc.org
frruberg@bu.edu

Sections

Cardiovascular Medicine

Centers

Whitaker Cardiovascular Institute

Amyloidosis Center

Biography

Frederick L. Ruberg, MD is the Thomas J. Ryan Professor of Cardiovascular Medicine and Professor of Radiology at Boston University (BU) Chobanian & Avedisian School of Medicine and Chief, Section of Cardiovascular Medicine at Boston Medical Center (BMC). Dr. Ruberg attended the University of Pennsylvania Perelman School of Medicine, completed internal medicine training at Brigham and Women’s Hospital, cardiovascular disease fellowship at Boston Medical Center/Boston University School of Medicine, followed by a fellowship in cardiovascular magnetic resonance (CMR) imaging at Beth Israel Deaconess Medical Center in Boston. Committed to research mentorship, he co-directs Workforce Development for the Boston University Clinical and Translational Science Institute (CTSI) and serves as Senior Associate Editor of Circulation: Cardiovascular Imaging. Dr. Ruberg is a Fellow of the American Heart Association and a member of the Association of University Cardiologists. His clinical and research expertise primarily involves cardiac imaging and infiltrative heart disease focused on improving the recognition and care of patients with cardiac amyloidosis, particularly that owing to ATTR and the hereditary genetic TTR variant Val122Ile (or V142I). He is an investigator on numerous NIH-funded awards including co-PI of the $7.2m NHLBI-funded Screening for Cardiac Amyloidosis with Nuclear Imaging (SCAN-MP, R01 HL139671) study. An active clinical cardiologist at the BU Amyloidosis Center, he has also contributed and co-directed numerous collaborative clinical guidelines initiatives, including mostly recently the 2023 the ACC Expert Consensus Decision Pathway document on The Comprehensive Multidisciplinary Care of Patient with Cardiac Amyloidosis. Dr. Ruberg has been recognized with mentorship (2017) and citizenship (2022) awards from the BU Department of Medicine.

Other Positions

Websites

BU Profile

Boston University School of Medicine Profile

Boston Medical Center Provider Profile

ResearchGate

Education

Medicine-Internal, MD, University of Pennsylvania School of Medicine

Psychology, BA, Haverford College

Publications

Published on 9/11/2025

Benz DC, Clerc OF, Cuddy SAM, Singh V, Kijewski MF, Bianchi G, Yee AJ, Ruberg FL, Jerosch-Herold M, Kwong RY, Di Carli MF, Liao R, Falk RH, Dorbala S. Changes in Myocardial Light Chain Amyloid Burden After Plasma Cell Therapy. JACC Cardiovasc Imaging. 2025 Sep 11. PMID: 40938234.

PubMed

Published on 9/10/2025

Ruberg FL, Teruya S, Helmke S, Smiley DA, Fine D, Kurian D, Raiszadeh F, Prokaeva T, Spencer B, Wong S, Pandey S, Blaner WS, DeLuca A, Johnson LL, Kinkhabwala MP, Leb J, Mintz A, LaValley MP, Einstein AJ, Cohn E, Gallegos C, Murtagh G, Kelly JW, Miller EJ, Maurer MS. Transthyretin Cardiac Amyloidosis in Older Black and Hispanic Individuals With Heart Failure. JAMA Cardiol. 2025 Sep 10. PMID: 40928765.

PubMed

Published on 7/17/2025

McMenamin KJ, Ruberg FL. High-Intensity Exercise, Fibrosis, and Ventricular Arrhythmias: How Much Is Too Much? Circ Cardiovasc Imaging. 2025 Aug; 18(8):e018716. PMID: 40675175.

PubMed

Published on 7/12/2025

Islam SJ, Teruya S, Fine D, Sabogal N, Fils S, Ullah I, Sanchorawala A, Miller E, Gallegos C, DE Freitas C, Kurian D, Ionescu N, Janvier I, Raiszadeh F, Benjamin EJ, Magnani JW, Maurer MS, Ruberg FL. Health Literacy and Physical Function Among Older Black and Hispanic Individuals With Heart Failure. J Card Fail. 2025 Jul 12. PMID: 40659241.

PubMed

Published on 5/27/2025

Regan JA, Kittleson MM, Khouri MG, Ruberg FL, Selvaraj S. Serum Transthyretin as a Biomarker of Treatment Response in ATTR Cardiomyopathy. J Am Coll Cardiol. 2025 May 27; 85(20):1924-1926. PMID: 40398972.

PubMed

Published on 5/27/2025

Siddiqi OK, Ruberg FL, Gopal DM. Impact of Vutrisiran on Functional Capacity and Quality of Life in ATTR Cardiomyopathy: HELIOS-B Analysis. J Am Coll Cardiol. 2025 May 27; 85(20):1956-1958. PMID: 40398974.

PubMed

Published on 5/1/2025

Griffin JM, Grodin JL, Ruberg FL, Masri A, Hanna M, Maurer MS. Current Landscape of Therapies for Transthyretin Amyloid Cardiomyopathy. JACC Heart Fail. 2025 May; 13(5):685-694. PMID: 40335224.

PubMed

Published on 3/25/2025

Edwards CV, Ferri GM, Villegas-Galaviz J, Ghosh S, Singh Bawa P, Wang F, Klimtchuk E, Ajayi TB, Morgan GJ, Prokaeva T, Staron A, Ruberg FL, Sanchorawala V, Giadone RM, Murphy GJ. Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition. Amyloid. 2025 Jun; 32(2):179-192. PMID: 40134188.

PubMed

Published on 2/21/2025

Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri A, Dunnmon P, Emdin M, Abou Ezzeddine OF, Falk RH, Fontana M, Grodin JL, Guthrie S, Jerosch-Herold M, Hofling AA, Hsu K, Lin G, Masri A, Maurer MS, Mittmann C, Prasad K, Quarta CC, Race JM, Rajendran JG, Ruberg FL, Sachdev V, Sanchorawala V, Signorovitch J, Sirac C, Soman P, Sorensen J, Sperry BW, Stephens AW, Stockbridge NL, Vest J, Wall JS, Wechalekar A, Welsh C, Lousada I. Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. JACC Cardiovasc Imaging. 2025 May; 18(5):602-617. PMID: 39985507.

PubMed

Published on 1/22/2025

Cheng RK, Leedy D, Ruberg FL. Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis? J Am Coll Cardiol. 2025 Feb 25; 85(7):762-765. PMID: 39846939.

PubMed

View full list of 158 publications.